During the past decade, Hiroshima City Hiroshima Citizens Hospital; Urology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hiroshima City Hiroshima Citizens Hospital; Urology" are "Bladder Cancer" (1 trials) and "Carcinoma, Transitional Cell" (1 trials). Many other conditions were trialed in "Hiroshima City Hiroshima Citizens Hospital; Urology" in a lesser frequency.

Most popular intervention types in "Hiroshima City Hiroshima Citizens Hospital; Urology" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody" (1 trials), "Docetaxel" (1 trials), "Paclitaxel" (1 trials) and "Vinflunine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hiroshima City Hiroshima Citizens Hospital; Urology" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Hiroshima City Hiroshima Citizens Hospital; Urology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Hiroshima City Hiroshima Citizens Hospital; Urology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hiroshima City Hiroshima Citizens Hospital; Urology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".